Abiopharma

🔍 MCCORMICK FRANK (Director)

Company: BridgeBio Pharma, Inc. (BBIO)

Report Date: 2025-09-05

Detailed Transactions and Holdings:

• Acquired 74,000 shares of Common Stock at $11.92 per share (Direct)
  Date: 2025-09-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 157,275.00 | transaction_form_type: 4
• Sold 74,000 shares of Common Stock at $53.156 per share (Direct)
  Date: 2025-09-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 83,275.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-05 | Code: H | nature_of_ownership: By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 | shares_owned_after: 879,979.00
• Sold 74,000 shares of Stock Option (Right to Buy) at $11.92 per share (Derivative)
  Date: 2025-09-05 | Code: M | Expires: 2033-02-20 | equity_swap_involved: 0 | shares_owned_after: 84,814.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents the weighted average sale price of the shares sold from $52.96 to $53.39 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
• F2: The stock option vests and becomes exercisable in three annual installments after February 21, 2023, with a final vesting date of February 21, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.
• REMARKS: Exhibit 24 - Power of Attorney